Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus fulvestrant or letrozole in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer after CDK4/6 inhibitor
jRCT2080223749Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of alpelisib in breast cancer (2 arms), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223749.